A Study With Imlifidase in Anti-GBM Disease

ClinicalTrials.gov ID: NCT05679401

Public ClinicalTrials.gov record NCT05679401. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.

Study identification

NCT ID: NCT05679401
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hansa Biopharma AB; Industry
Enrollment: 50 participants

Conditions and interventions

Conditions

Interventions

Drug · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 22, 2022 (Actual)
Primary completion: Jun 23, 2025 (Actual)
Completion: Feb 2, 2026 (Actual)
Last update posted: Mar 4, 2026

2022 – 2026

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
UCLA Medical Center Plaza	Los Angeles	California	90024	—
John Hopkins Medical Institution	Baltimore	Maryland	21287	—
Brigham and Women's Hospital	Boston	Massachusetts	02115	—
University of Minnesota Health Clinical Research Unit	Minneapolis	Minnesota	55455	—
UNC Kidney Center/Division of Nephrology & Hypertension	Chapel Hill	North Carolina	27599-7155	—
The Ohio State University Wexner Medical Center	Columbus	Ohio	43201	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05679401, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 4, 2026 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05679401 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →